Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Core Insights - Syndax Pharmaceuticals granted inducement awards to purchase up to 499,200 shares of common stock to fifty-three new employees under the Company's 2023 Inducement Plan [1] - The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remaining shares vesting monthly thereafter [1] Company Overview - Syndax is a clinical-stage biopharmaceutical company focused on developing an innovative pipeline of cancer therapies [2] - Key products in the pipeline include revumenib, a selective menin inhibitor, and axatilimab, a monoclonal antibody targeting the CSF-1 receptor [2]